Introduction: Looking back at the initially dismal record for pancreat
ic cancer surgery - Whipple himself felt that a 30-35% mortality was j
ustifiable (!)-significant progress has been made. Progress: The opera
tive mortality has fallen below 5% and the serious complications of pa
ncretic resections such as leaks and haemorrhage have been reduced to
some 10% and we are better equipped to deal with these if they occur.
The 5-year-survival of patients in whom pancreatic cancer was amenable
to an RO-resection has risen to 30%. These are the surgical achieveme
nts using the standard Kausch-Whipple technique alone. There has been
no improvement in these results, either by increasing radicality (regi
onal pancreatectomy) or by reducing it (pylorus-preserving pancreatodu
odenectomy). The same can be said of all other modalities of oncologic
al treatment that have been tried so far: adjuvant radiochemotherapy,
regional chemotherapy, hormonal or genetic manipulations. Perspective:
This does not mean that we should reduce efforts at improving early d
etection of the disease and unravelling its complex molecular biology.
On the contrary, the results of surgery alone in spite of all improve
ments seem to have reached a plateau that gives little cause for compl
acency.